Strategic Partners SR-Tiget is a joint venture between Fondazione Telethon and Ospedale San Raffaele, located in Milan within a multidisciplinary research ecosystem. This suggests strong alignment for partnerships with biotech companies, philanthropic funders, and hospital-based collaborators to co-develop gene and cell therapies.

Clinical Track Record The institute has led multiple gene therapy clinical trials for inherited immunodeficiencies and lysosomal storage disorders, with over 160 patients treated and 3 novel advanced therapy medicines filed or approved. This demonstrates credibility for partnering in late-stage development, manufacturing collaborations, and access to translational expertise.

Therapy Expansion Recent activity includes expanding applications of cell and gene therapy platforms into oncology-focused strategies, indicating potential for collaboration on cancer gene therapies and joint development programs with pharma partners.

Funding & Scale Operating with revenue in the low millions and a sizeable employee base, SR-Tiget sits in a favorable position to pursue co-funding, grant-enabled programs, and strategic investment opportunities with industry partners seeking academic and translational capabilities.

Global Outreach The institute’s established international collaborations (e.g., with Novartis and Regeneron in CRISPR ventures) and participation in major conferences position it well for outbound BD efforts, licensing deals, and collaborative R&D ventures with global biotech players.